WRF
ENTA icon

Waddell & Reed Financial’s Enanta Pharmaceuticals ENTA Stock Holding History

Waddell & Reed Financial’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-110,500
Closed -$3.65M – 602
2015
Q4 		$3.65M Hold
110,500
– – 0.01% 526
2015
Q3 		$3.99M Buy
+110,500
New +$4.75M 0.01% 518

Other funds holding ENTA

ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Waddell & Reed Financial's ENTA Position: Q1 2016 in Review

Waddell & Reed Financial sold out of Enanta Pharmaceuticals (ENTA) in Q1 2016, closing a stake of 110,500 shares — an estimated $3.65M sold.

Waddell & Reed Financial first reported a position in ENTA in Q3 2015 and held it in 2 quarters. The position peaked at $3.99M in Q3 2015. 152 funds tracked by Wall St. Rank hold ENTA as of Q1 2016.

  • Waddell & Reed Financial reported no remaining Enanta Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Waddell & Reed Financial sold 110,500 Enanta Pharmaceuticals shares in Q1 2016, an estimated $3.65M.
  • Waddell & Reed Financial first reported a position in Enanta Pharmaceuticals in Q3 2015 and held it in 2 quarters.
  • Waddell & Reed Financial's Enanta Pharmaceuticals position peaked at $3.99M in Q3 2015.
  • 152 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2016.

Based on Waddell & Reed Financial's 13F filing for Q1 2016, filed 13 May 2016.